(Alliance News) - DiaSorin Spa announced on Tuesday that the US Food and Drug Administration has approved the LIAISON QuantiFERON-TB Gold Plus II test, developed in collaboration with QIAGEN NV, designed "to enhance laboratory productivity, workflow efficiency,
and turnaround times for latent tuberculosis infection testing in the USA."
The new product will enable laboratories to analyze over 75% more patients per hour, with response times 25% faster.
It is estimated that LTBI affects about 25% of the global population, with up to a 10% risk of progressing to active disease if left untreated.
Since 2017, more than 7,000 LIAISON XL systems have been installed worldwide, allowing high-volume laboratories to process the QuantiFERON-TB Gold Plus II test with minimal manual intervention, full traceability, and optimal IT integration.
"With the launch of the LIAISON QuantiFERON-TB Gold Plus II in the USA, DiaSorin further strengthens its leadership in specialized diagnostics and consolidates its long-standing partnership with QIAGEN," commented Carlo Rosa, CEO of DiaSorin.
The new LIAISON QuantiFERON-TB Gold Plus II test on LIAISON XL will be available in the USA at the end of March 2026, following its availability in all countries recognizing CE marking starting from November 2025.
DiaSorin shares are down 0.2% at EUR70.06 per share.
By Michele Cirulli, Alliance News Reporter
Comments and questions to redazione@alliancenews.com
Copyright 2026 Alliance News IS Italian Service Ltd. All rights reserved.
